Livedoid vasculopathy (LV) is a thrombo-occlusive vasculopathy that involves the dermal vessels. Clinically, it is characterized by the presence of painful purpuric ulcers on the lower extremities. Histopathologically, it shows intraluminal fibrin deposition and thrombosis, segmental hyalinization, and endothelial proliferation. It is important to notice that the term "atrophie blanche" is descriptive and it includes not only patients with LV but also patients with a combination of vasculitis and vasculopathy, that is, LV and medium-sized vasculitis such as cutaneous polyarteritis nodosa (PANc). Diagnosis is based on a proper clinicopathological correlation, excluding the main differential diagnosis and considering vasculitis as a mimicker or concomitant diagnosis. Coagulation disorders must also be studied although they are not found in all LV. Its frequency is reviewed as well. Treatment of LV is challenging, and different therapies have been attempted. Among them, pain management, wound care, control of cardiovascular risk factors, and both antiplatelets and anticoagulants, mostly rivaroxaban, are the main therapies used. These different therapies as well as their degree of evidence are reviewed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773082PMC
http://dx.doi.org/10.3389/fmed.2022.993515DOI Listing

Publication Analysis

Top Keywords

livedoid vasculopathy
8
comprehensive review
4
review pathogenesis
4
pathogenesis associations
4
associations clinical
4
clinical findings
4
findings treatment
4
treatment livedoid
4
vasculopathy
4
vasculopathy livedoid
4

Similar Publications

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review.

J Dermatolog Treat

December 2025

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV. A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.

View Article and Find Full Text PDF

A 58-year-old female smoker diagnosed with myelodysplastic syndrome (MDS) presented with Raynaud's phenomenon and a "scleroderma-like" pattern on nailfold capillaroscopy. The capillaroscopic abnormalities were observed across all fingers, including those without clinical manifestations of onychomycosis. Over a two-year follow-up, there was no evidence of clinical or serological progression toward a connective tissue disease, particularly systemic sclerosis.

View Article and Find Full Text PDF

Objectives: To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud's phenomenon (RP).

Methods: We retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud's Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up.

View Article and Find Full Text PDF

Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers.

Ann Hematol

December 2024

Division of Hematology, Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, United States of America.

Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!